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BUPRENORPHINE WITHDRAWAL SYNDROME 
B.M.TRIPATHI, P.HEMRAJ, N.K.DHAR 
T)\e increasing use of buprenorphine among drug dependent subjects demands systematic enquiry into 
the clinical profile of buprenorphine withdrawal. Six male buprenorphine dependent (parenteral) 
subjects were observed for opiate withdrawal owr a two week period. The onset of withdrawal occurred 
48 hours after the last dose, peaked around the third day and lasted up to ten days. The withdrawals 
were similar to morpliine type drugs and moderate in intensity. 
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INTRODUCTION 
The use of buprenorphine, a narcotic analgesic, 
has increased in drug using populations all over the 
world. Since early reports of buprenorphine abuse, 
its abuse liability and dependence potential have 
been demonstrated (Quigley el al, 1984; O'Connor 
et al, 1988; Lai, 1992). The risk of buprenorphine 
abuse is magnified in heroin users because of its use 
as a detoxifying agent (Kosten, 1988; Bickel. 1988) 
and maintenance agent (Seow et al, 1986; Reisinger, 
1985). Though a buprenorphine withdrawal 
syndrome has been described, it needs to be 
delineated further (Fudala et al, 1990; San et al, 
1992). The withdrawal profile in buprenorphine de-
pendent persons has been examined in the current 
study. 
MATERIALS AND METHODS 
Six male patients who were hospitalized for the 
treatment of buprenorphine dependence syndrome, 
diagnosed using DSM III-R (APA, 1987) criteria 
and who had used buprenorphine within the last 48 
hours were included in the study, after obtaining 
consent. Patients who had used other morphine type 
drugs during the previous month were excluded. 
Urinary screening by thin layer chromatography was 
done at the time of admission as well as during the 
stay in hospital for identification of drugs used. The 
patients were given benzodiazepines (nitrazepam) 
and/or non-narcotics analgesics (diclofenac sodium 
or ibuprofen) when needed during hospitalization. 
The opioid withdrawal symptoms were recorded 
for a fortnight between 9 and 10 a.m. using the 
Opiate Withdrawal Rating Scale (Handelsman et al, 
1987). This has two sub-scales, viz, subjective 
(SOWS) and objective (OOWS) withdrawal scales 
for recording subjective and objective opiate 
withdrawal symptoms. Subjective referred to those 
symptoms that were either reported in the past 24 
hours or at the time of examination. Objective 
symptoms were present at the time of examination. 
The resident in charge of the patients rated the 
withdrawal profile. Since the scale had been used 
routinely in clinical practice, the raters were familiar 
with the rating method. 
RESULTS 
The patients were between 24 and 51 years of age 
(36.16 ± 9.9 years). The duration of buprenorphine 
use was 3.16 ± 1.55 years. Out of the six patients, 
four had been heroin users and started buprenor-
phine in an attempt to give up heroin; one had used 
pentazocine prior to buprenorphine and the other 
patient started buprenorphine use due to a physical 
ailment. All of them were primarily parenteral users 
and had used the sublingual mode of administration 
only rarely. Two patients used promethazine (25-50 
mg/day) and one used diazepam (10 mg/day) in 
addition to buprenorphine. The daily does of 
buprenorphine was 2.55 ± 1.22 mg parenterally. 
None of them were HJV positive in a pre-admis-
sion screening using El .ISA. Diclofenac sodium (50 
mg) or ibuprofen (400 to 600 mg) were used when 
necessary; these were needed till the second week in 
four patients. Nitrazepam (10 to 40mg) was given to 
all patients until the second week. 
The withdrawal profile as indicated by the Opiate 
Withdrawal Rating Scale (Handelsman et al, 1987) 
shows that predominant subjective complaints were 
anxiety, yawning, bone and muscle aches and rest-
lessness. These complaints started on the second day 
after the last dose of buprenorphine, peaked on the 
third and fourth days and lasted up to a fortnight (Fig 
1). The SOWS scores on the first, third and four-
teenth day were 8.33 ±6.34,10.4± 5.7 and 1.5± 0.12 
respectively. 
Common objective withdrawal features were 
yawning, rhinorrhoca, lacrimation, mydriasis, rest-
lessness and anxiety. These started on the second 
day, peaked on the third day and lasted till the 
twelfth day (Fig. 1). Anxiety and restlessness lasted 
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for a week. Mydriasis and lacrimation persisted till 
the tenth day. The OOWS on the first, third and 
twelfth days were 2.0 ±234, 2.5* 1.6 and 0.3* 0.5 
respectively. 
DISCUSSION 
Though buprenorphine was considered to be an 
opioid analgesic with low abuse potential and de-
pendence liability, its dependence potential has been 
established. Dependent use of buprenorphine has 
been documented in heroin users (Quigley et al, 
1984; Rainey, 1986; O'Connor et al, 1988; Lai, 
1992). 
Buprenorphine withdrawal appears within 48 
hours after the last dose, peaks around the third or 
fourth day and lasts for ten days. These withdrawal 
symptoms are moderate in severity. These findings 
are similar to the reports by San et al (1992) and 
Fudala ct al (1990), and contrary to the earlier 
reports of later onset andmild intensity of buprenor-
phine withdrawal. The withdrawal profile is similar 
to other morphine type drugs. The subjective scores 
were higher in comparison to the objective scores, 
which means that the reported subjective distress is 
much more than the objective signs of withdrawal. 
Buprenorphine should be cautiously used as a 
detoxifying and maintenance agent in heroin de-
pendent subjects. It is also suggested that the patients 
undergoing withdrawal from buprenorphine may 
need medication because of moderately severe 
symptoms. 
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